The medical device maker raised full-year EPS guidance to $4.70-$4.80 after strong U.S. spine sales and margin expansion.
Globus Medical reported first-quarter revenue of $759.9 million, up 27% year over year, driven by U.S. spine momentum, margin expansion, and contributions from its Nevro acquisition. Non-GAAP diluted EPS rose 64.7% to $1.12.
U.S. spine sales grew for the third consecutive quarter at 10%, marking 58 straight weeks of gains. Executives attributed growth to market share gains, cross-selling, and robotics pull-through, with international spine also contributing. The company reaffirmed full-year revenue guidance of $3.18 billion to $3.22 billion but raised EPS guidance to $4.70-$4.80 from $4.40-$4.50.
Nevro revenue is expected to remain uneven in the near term as integration continues, with improvement anticipated later in 2026. Management highlighted operational discipline and progress since 2022, including a sixfold increase in free cash flow and $1 billion in debt reduction.